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Introduction. Intra-amniotic infection (IAI) is a major cause of preterm labor and adverse neonatal outcome. We evaluated
amniotic fluid (AF) proteolytic cascade forming biomarkers in relation to microbial invasion of the amniotic cavity (MIAC)
and IAI in preterm pregnancies with intact membranes. Material and Methods. Amniocentesis was made to 73 women with
singleton pregnancies; 27 with suspected IAI; and 46 controls. AF biomarkers were divided into three cascades: Cascade 1: matrix
metalloproteinase-8 (MMP-8), MMP-9, myeloperoxidase (MPO), and interleukin-6; Cascade 2: neutrophil elastase (HNE), elafin,
and MMP-9; Cascade 3: MMP-2, tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), MMP-8/TIMP-1 molar ratio, and C-
reactive protein (CRP).MMP-8wasmeasured by an immunoenzymometric assay and the othersweremeasured byELISA. Standard
biochemical methods, molecular microbiology, and culture techniques were used. Results. MMP-8, MMP-9, MPO, elafin, and
TIMP-1 concentrations were higher in IAI suspected cases compared to controls and also in IAI suspected cases with MIAC
compared to those without MIAC when adjusted by gestational age at amniocentesis. All biomarkers except elafin andMMP-2 had
the sensitivity of 100% with thresholds based on ROC-curve. Odd ratios of biomarkers for MIAC were 1.2-38 and 95% confidential
intervals 1.0-353.6. Conclusions. Neutrophil based AF biomarkers were associated with IAI and MIAC.
1. Introduction
Intra-amniotic infection (IAI), defined as microbial invasion
of the amniotic cavity (MIAC) with intra-amniotic inflam-
mation, is common in women with preterm labor and exists
with or without preterm prelabor rupture of membranes
(PPROM) [1]. MIAC often leads to IAI [2]. However, intra-
amniotic inflammation in the absence of MIAC also occurs
[3]. Amniocentesis and amniotic fluid (AF) rapid biomarker
testing may help in optimal timing of delivery.
Infection may induce the degranulation of interleu-
kin- (IL-) 6 and matrix metalloproteinases (MMP), from
polymorphonuclear neutrophils (PMNs) [4]. MMP-8 has
been linked to MIAC [5–7], inflammation [8–10], histo-
logical chorioamnionitis (HCA) [11], and adverse neonatal
outcome [12, 13]. Several AF biomarkers form proteolytic
cascades. They are formed in inflammatory conditions after
recruitment and activation of neutrophils, which release their
subcellular granules, that is, degranulating tissue destructive
enzymes (for example, MMP-8, MMP-9, and neutrophil
elastase (HNE)). Those and other such enzymes can form
cascades by activating each other.The process leads to degra-
dation of extracellular matrix components and modulation
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Table 1: Selected characteristics of the study population.
Cases (𝑁 = 27) Controls (𝑁 = 46) 𝑝 value
Maternal age, median (range) 31 (20–43) 32.5 (17–48) 0.23
Nulliparous, 𝑛 (%) 10 (37) 21 (46) 0.47
BMI, median (range)∗ 27 (20–49) 25.5 (18–48) 0.77
Smoking, 𝑛 (%) 5 (18.5) 9 (20) 0.91
Gestational diabetes, 𝑛 (%) 5 (18.5) 18 (39) 0.067
AC-delivery interval in weeks, median (range) 7.4 (0–17.7) 8.2 (0–24.3) 0.032
Gestational age at AC in weeks, median (range) 27.6 (22–32) 23.1 (17–38) 0.54
Gestational age at delivery in weeks, median (range) 37.9 (24–42) 38.3 (28–42) 0.013
∗Missing 𝑛 = 1.
BMI, body mass index; AC, amniocentesis.
of cytokines [4], which may lead in obstetrics to membrane
rupture or ripening and softening of the cervix.
MPO is the activator of MMP-8 and MMP-9, while IL-
6 can act as their inducer (Cascade 1). HNE is an activator
of MMP-9, and elafin is an antiprotease of HNE [14]. Elafin
is produced not only by neutrophils but also by epithelial
cells [14]. Thus, HNE and MMP-9 form another PMN-
derived proteolytic cascade (Cascade 2), to which elafin asso-
ciates. The third cascade comprises MMP-2, tissue inhibitor
of matrix metalloproteinases-1 (TIMP-1), MMP-8/TIMP-1
molar ratio, andC-reactive protein (CRP) (Cascade 3).MMP-
2 and TIMP-1 are not produced by PMNs.
While many reports on AF biomarkers in PPROM preg-
nancies exist, such studies of MIAC and IAI in preterm
pregnancies with presumed intact membranes are only few
[3, 15, 16].
2. Materials and Methods
This prospective study was conducted at the Department
of Obstetrics and Gynecology, University Hospital, Helsinki,
Finland, between June 2013 and October 2015. The Insti-
tutional Review Board approved the study protocol (Ref.
number 75/13/03/03/2013). A written informed consent was
obtained from all patients.
2.1. Patients. The study population consisted of 73 women
who underwent amniocentesis with singleton pregnancy
and presumed intact membranes. Twenty-seven women had
suspected IAI. Among those, the median gestational age at
amniocentesis was 27+4 weeks, ranging from 22+0 to 31+4.
IAI was suspected in the presence of preterm contractions
with at least one of the following criteria: uterine tenderness,
fetal tachycardia, infectious discharge from cervix, maternal
plasma CRP > 10mg/L, total blood white cell (WBC) count
> 20 × 109/L, or visible sludge at ultrasound examination.
Forty-six pregnant women with no suspected IAI served as
controls (Table 1). In the control group the indication for
amniocentesis was mid-trimester chromosomal analysis in
24 cases (52%), evaluation of fetal lung maturity [𝑛 = 5
(11%)], or exclusion of fetal chronic hypoxia by erythropoietin
measurement [𝑛 = 17 (37%)]. Among controls, the gesta-
tional age at amniocentesis was (median, range) 23+1 weeks
(from 17+0 to 37+5). In the control group, five (11%) developed
preeclampsia, four (9%) had insulin treated gestational dia-
betes, and four (9%) pregnancies were complicated by fetal
growth restriction (fetal growth below -2 SD). Fetal structural
anomaly, proven or suspected fetal aneuploidy, and diabetes
type I were not eligible.
Gestational age was based on the first trimester ultra-
sonography screening. Membranes were presumed intact in
the absence of any clinical signs of membrane rupture.
2.2. Collection of Samples and Laboratory Procedures. Trans-
abdominal amniocentesis was performed by our study group
members. AF samples were retrieved. MIAC was defined as
a positive AF culture or positive bacterial PCR by 16S rRNA
gene sequencing. The result of bacterial culture was available
in 23 (85%) cases and in none of the controls and the result
of AF-PCR in all cases and controls. The microbial analyses
have been described in detail previously [15].
AF specimens were divided into aliquots, frozen and
stored at −20∘C until the biomarkers were analysed (Medix
Biochemica, Espoo, Finland). AF-MMP-8 quantitation
was made with a solid-phase immunoenzymometric assay
(MMP-8 IEMA, Medix Biochemica, Espoo, Finland) and it
was analysed according to the manufacturer’s instructions.
The absorbance measurement was done at 414 nm using
a microplate reader (Multiskan, Thermo Fisher Scientific,
Vantaa, Finland). Other biomarkers were analysed by using
commercial enzyme-linked immunosorbent assay (ELISA):
AF-elafin [Human Trappin-2 (elafin) ELISA kit, RayBiotech,
Norcross, GA,USA], AF-HNE [polymorphonuclear (Human
PMN Elastase) Sandwich ELISA kit, eBioscience, Vienna,
Austria], AF-IL-6 [interleukin-6 (IL-6) ELISA kit, R&D
Systems, Minneapolis, USA], AF-MPO [myeloperoxidase
(MPO) ELISA kit, Immundiagnostik AG, Bensheim, Hesse,
Germany], AF-MMP-2 [matrix metalloproteinase-2 (MMP-
2) ELISA kit, R&D Systems, Minneapolis, USA], AF-MMP-9
[matrix metalloproteinase-9 (MMP-9) ELISA kit, R&D
Systems, Minneapolis, USA], AF-CRP [human C-reactive
protein (CRP) ELISA kit, R&D Systems, Minneapolis, USA],
and AF-TIMP-1 [tissue inhibitor of metalloproteinases 1
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(TIMP-1) ELISA kit, GE Healthcare, Buckinghamshire, UK].
The inter- and intra-assay coefficients of variation for elafin
were <10% and <12%, respectively; for HNE < 5% and <
6%, respectively; for IL-6 < 5% and < 5%, respectively; for
MPO < 3% and < 5%, respectively; for MMP-2 < 7% and <
13%, respectively; for MMP-8 < 6% and < 6%, respectively;
for MMP-9 < 3% and < 8%, respectively; for CRP < 10%
and < 10%, respectively; and for TIMP-1 < 12% and < 16%,
respectively.The limit of detection for elafinwas 0.005 ng/mL,
for HNE 0.00198 ng/mL, for IL-6 0.0007 ng/mL, for MPO
0.294 ng/mL, for MMP-2 0.37 ng/mL, for MMP-8 0.4 ng/mL,
for MMP-9 0.156 ng/mL, for CRP 0.010 ng/mL, and for
TIMP-1 1.25 ng/mL. For AF-LD the intra-assay coefficient
of variation (CV) was <2.3% and the limit of detection of
the assay was 5 IU/L. For AF-Gluc the detection limit was
0.50mmol/L. In the concentration levels less than 4mmol/L
the intra-assay CVwas 4.7% and at concentration levels from
4.1mmol/L to 42mmol/L 1.9%.
Patients were managed according to our clinical practice
guidelines. During the study period, only the results of AF-
lactate dehydrogenase (LD), AF-glucose (Gluc), AF-PCR,
and AF bacterial culture were available to obstetricians in
charge. The methods of AF-LD and AF-Gluc testing have
been described previously [15, 17]. If AF-LD was less than
419 IU/L and AF-Gluc was more than 0.7mmol/L [15] in the
absence of MIAC, pregnancy could continue and patients
were followed up as outpatients.
MMP-8 belongs to proinflammatory neutrophil based
cascade but represents also a known biomarker in this study.
The cut-off value for AF-MMP-8 was 41.5 ng/mL, which
has shown a sensitivity of 100%, specificity of 69%, PPV of
62%, and NPV of 100% for MIAC in a previous study [18]
and was considered consistent with inflammation. IAI was
determined as AF-MMP-8 > 41.5 ng/mL in the presence of
MIAC.
2.3. Neonatal Outcome. Data on deliveries (spontaneous,
induced, or caesarean section) and neonates were collected
from the hospital records. The short-term outcome variables
for neonates were birth weight, Apgar score at 1min and
5min of age, umbilical artery pH and base excess (BE), need
for neonatal intensive care unit, need for a respirator, and the
presence of clinical sepsis or blood culture positive sepsis.
CRP and WBC levels were recorded.
The diagnosis of neonatal sepsis was set by a neonatolo-
gist. Neonatal sepsis was categorized into clinical sepsis and
blood culture positive sepsis. Clinical sepsis was defined as
blood culture negative infection with symptoms consistent
with sepsis, abnormal blood values, and positive response
to a minimum of 5-day antibiotic treatment. Abnormal
blood values supporting clinical sepsis diagnosis included
elevatedCRPmore than 20mg/L, leukocytosis or leukopenia,
increased neutrophil precursors, thrombocytopenia, and no
signs of other infections.The symptoms of clinical sepsis were
respiratory distress, apnoea, tachycardia, poor perfusion,
low blood pressure, fever, hypoglycaemia, hyperglycaemia,
irritability, feeding problems, lethargy, and convulsions.
Sepsis was categorized as present or absent. All neonates
with clinical or blood culture positive sepsis received
antibiotics.
Other outcome measures for neonates were respira-
tory distress syndrome (RDS), bronchopulmonary dysplasia
(BPD), necrotising enterocolitis (NEC), retinopathy of pre-
maturity (ROP), intraventricular hemorrhage (IVH), periv-
entricular leukomalacia (PVL), or death.
2.4. Statistical Analysis. All calculations were carried out
using Microsoft Statistical Package for Social Sciences (SPSS
Inc., Chicago, IL, USA) for Windows v22.0. Categorical
variables were compared by the chi-square test or Fisher’s
exact test if the number of cases was under five. Data with
continuous variables did not follow a normal distribution
and were compared by Mann–Whitney 𝑈 test. Amniotic
fluid biomarkers were regressed on gestational age at sample
collection and on gestational age at delivery, and adjusted
𝑝 values were computed using the residual as a dependent
variable. The correlations of biomarker concentrations with
MMP-8 were tested with Spearman bivariate correlation.
The receiver operating characteristics (ROC) curve was
constructed, area under the curve (AUC) was estimated,
and the sensitivity and specificity were calculated. Two-tailed
tests were used. A 𝑝 value less than 0.05 was considered
significant.
3. Results
Theselected characteristics of the study population are shown
inTable 1.MIACwas found in 7women (26%)with suspected
IAI (cases) and in none of the controls. Candida species were
detected in two cases; other microbes (six different) were
detected in one case each. MIAC was polymicrobial in one
case (14%).
3.1. AF Biomarkers
Cascade 1. As shown in Table 2, the median concentrations
of all biomarkers were higher in IAI suspected cases than in
controls. When adjusted by gestational age at amniocentesis,
all biomarkers except AF-IL-6 were higher in IAI suspected
cases than in controls (Table 2). Among IAI suspected
cases, all biomarkers were associated with MIAC, also when
adjusted by gestational age (Table 3). The accuracies and the
most optimal cut-off values based on ROC-curve are shown
in Table 4. Among Cascade 1 biomarkers, MMP-9 had the
highest risk for MIAC, OR 4.5 (95% CI 1.3–15.3) (Table 4).
Cascade 2. The median concentration of HNE did not differ
between cases and controls, but the median concentration of
elafin and MMP-9 was higher in cases than in controls, also
when adjusted by gestational age (Table 2). All biomarkers in
Cascade 2 were associated withMIAC, also when adjusted by
gestational age (Table 3).The accuracies and themost optimal
cut-off values based on ROC-curve are shown in Table 4.
Cascade 3. The median concentrations of all biomarkers
except AF-CRP were higher in cases than in controls
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Table 2: Amniotic fluid biomarker concentrations in IAI suspected cases and controls.
Biomarker ng/mL Cases (𝑁 = 27) Controls (𝑁 = 46) 𝑝 value Adjusted 𝑝 value∗
Cascade 1
MMP-8 11 (3–5431) 4.5 (2–76) <0.001 0.004
MMP-9 10 (0.7–9678) 2.6 (0.6–19) 0.003 0.005
MPO 362 (75.6–79095) 80 (8.6–488) <0.001 <0.001
IL-6 1.1 (0.03–1021) 0.4 (0.06–8.2) 0.004 0.163
Cascade 2
HNE 19 (2.8–16380) 23 (1.5–200) 0.51 0.444
Elafin 288 (7–10491) 74.5 (7–3739) 0.001 0.002
MMP-9 10 (0.7–9678) 2.6 (0.6–19) 0.003 0.005
Cascade 3
MMP-2 296 (153–938) 216 (72–505) 0.01 0.01
TIMP-1 1347 (633–9752) 1112 (505–3473) 0.011 0.022
MMP-8 /TIMP-1 molar ratio 0.005 (0.001–0.973) 0.002 (0–0.014) <0.001 0.069
CRP 43 (5–1783) 28.8 (5–670) 0.343 0.424
Biomarkers routinely used in clinical practice
LD IU/L∘ 234 (88–5459) 14.5 (4.0–156) <0.001
Gluc mmol/L∘ 1.9 (0.0–4.0) 1.7 (0.3–4.9) 0.585
Median (range).
∘Missing 𝑛 = 2 in controls.
∗Adjusted by gestational age at amniocentesis.
MIAC, microbial invasion of the amniotic cavity.
MMP-8, matrix metalloproteinase-8; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; IL-6, interleukin-6; MMP-2, matrix metalloproteinase-2;
HNE, neutrophil elastase; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; CRP, C-reactive protein; LD, lactate dehydrogenase; Gluc, glucose.
Table 3: Amniotic fluid biomarker concentrations in IAI suspected cases with or without MIAC.
Biomarker ng/mL MIAC+ (𝑁 = 7) MIAC− (𝑁 = 20) 𝑝 value Adjusted 𝑝value∗
Cascade 1
MMP-8 3019 (69–5431) 7.5 (3–2372) <0.001 <0.001
MMP-9 2981 (84–9678) 3.4 (0.7–730) <0.001 <0.001
MPO 4866 (267–79095) 299 (75.6–55185) 0.002 0.001
IL-6 94.9 (5.6–540) 0.6 (0.03–1021) <0.001 0.002
Cascade 2
HNE 11280 (315–16380) 12.3 (2.8–9862) <0.001 <0.001
Elafin 1533 (58–10491) 191 (7–4642) 0.031 0.016
MMP-9 2981 (84–9678) 3.4 (0.7–730) <0.001 <0.001
Cascade 3
MMP-2 311 (266–938) 231.5 (153–696) 0.081 0.055
TIMP-1 3958 (1456–9752) 1178 (633–9317) 0.001 0.001
MMP-8 /TIMP-1 molar
ratio 0.167 (0.011–0.973) 0.004 (0.001–0.155) <0.001 <0.001
CRP 133 (23–1783) 42.5 (5–985) 0.092 0.092
Biomarkers routinely used
in clinical practice
LD IU/L 1689 (337–5459) 185.5 (88–1521) <0.001
Gluc mmol/L 0.1 (0.0–1.5) 2.0 (0.0–4.0) <0.001
Median (range).
∗Adjusted by gestational age at amniocentesis.
MIAC, microbial invasion of the amniotic cavity.
MMP-8, matrix metalloproteinase-8; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; IL-6, interleukin-6; HNE, neutrophil elastase; MMP-2,
matrix metalloproteinase-2; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; CRP, C-reactive protein; LD, lactate dehydrogenase; Gluc, glucose.
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Table 4: The accuracies of biomarkers based on ROC-curve and the odd ratios OR (95% CI) for MIAC.
Cut-off value ng/mL AUC (95% CI) Sensitivity Specificity OR (95% CI)
Cascade 1
MMP-8 48 0.985 (0.96–1.0) 100 95.5 3.3 (1.3–8.6)
MMP-9 57.5 0.991 (0.97–1.0) 100 97 4.5 (1.3–15.3)
MPO 264 0.952 (0.88–1.0) 100 74.2 1.4 (1.1–1.8)
IL-6 5.1 0.974 (0.94–1.0) 100 93.9 2.8 (1.3–6.0)
Cascade 2
HNE 257 0.987 (0.97–1.0) 100 97 4.5 (1.3–15.3)
Elafin 488.5 0.854 (0.68–1.0) 85.7 86.4 38 (4.1–353.6)
MMP-9 57.5 0.991 (0.97–1.0) 100 97 4.5 (1.3–15.3)
Cascade 3
MMP-2 300.5 0.781 (0.65–0.91) 85.7 71.2 14.8 (1.7–131.7)
TIMP-1 1420.5 0.933 (0.87–1.0) 100 80.3 1.5 (1.1–2.1)
MMP-8 /TIMP-1 molar ratio 0.01 0.985 (0.96–1.0) 100 93.9 2.8 (1.3–6.0)
CRP 22 0.738 (0.56–0.91) 100 40.9 1.2 (1.0–1.3)
MIAC, microbial invasion of the amniotic cavity.
MMP-8, matrix metalloproteinase-8; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; IL-6, interleukin-6; HNE, neutrophil elastase; MMP-2,
matrix metalloproteinase-2; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; CRP, C-reactive protein; LD, lactate dehydrogenase; Gluc, glucose.
Table 5: Inflammation and MIAC by gestational age at delivery among cases.
<32 + 0 weeks >32 weeks 𝑝 value
𝑛 11 16
Gestational age in weeks at AC 29 (27–31) 30 (22–31) 0.8
AF MMP-8 concentration at AC, ng/mL 2131 (3–5431) 7.1 (3.1–144) 0.019
AF inflammation, 𝑛 (%) 8 (73%) 1 (6%) 0.031
AF MIAC, 𝑛 (%) 6 (55%) 1 (6%) 0.10
Spontaneous preterm birth < 7d
following AC, 𝑛 (%) 6 (55%) 0 <0.001
Median (range).
Inflammation, MMP-8 > 41.5 ng/mL.
AF, amniotic fluid.
AC, amniocentesis.
MIAC, microbial invasion of the amniotic cavity.
MMP-8, matrix metalloproteinase -8.
(Table 2). When adjusted for gestational age only MMP-
2 and TIMP-1 concentrations differed between cases and
controls (Table 2). TIMP-1 and MMP-8/TIMP-1 molar ratio
were associated with MIAC in IAI suspected cases. MMP-2
andCRPwere not associatedwithMIAC, evenwhen adjusted
by gestational age (Table 3). The accuracies and the most
optimal cut-off values based on ROC-curve are shown in
Table 4.
Among IAI suspected cases, AF-HNE had the highest
correlation with AF-MMP-8 (𝑟
𝑠
= 0.749, 𝑝 < 0.001), while
AF-MMP-2 had the lowest one (𝑟
𝑠
= 0.401, 𝑝 = 0.038).
Among controls AF-HNE had the highest correlation with
AF-MMP-8 (𝑟
𝑠
= 0.671, 𝑝 < 0.001). The correlations
of biomarkers except MMP-8 with MMP-8 separately in IAI
suspected cases and in controls are shown in Figures 1 and 2.
In IAI cases (MMP-8 > 41.5 ng/mL with MIAC) AF-CRP
correlated with MMP-8 (𝑟
𝑠
= 0.501, 𝑝 = 0.008), MMP-9 (𝑟
𝑠
=
0.493, 𝑝 = 0.044), MPO (𝑟
𝑠
= 0.645, 𝑝 < 0.001), IL-6 (𝑟
𝑠
=
0.473, 𝑝 = 0.013), and MMP-8/TIMP-1 molar ratio (𝑟
𝑠
=
0.556, 𝑝 = 0.003).
All biomarkers included were associated with IAI (𝑝 <
0.05) and all except MMP-2 (𝑝 = 0.053) were associated with
AF inflammation (𝑝 < 0.002) (data not shown).
3.2. Neonatal Outcome. Of all IAI suspected cases, 11
neonates (41%) were born before 32 gestational weeks. Of
these 11, six were born spontaneously within 7 days from
amniocentesis (Table 5). Four of these were born after induc-
tion of labor due to suspected infection and one was born
with caesarean section due to massive maternal hemorrhage.
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Figure 1: Correlation of other AF biomarkers with AF-MMP-8 among IAI suspected cases. Correlation values were (a) MMP-9 (𝑟
𝑠
= 0.71,
𝑝 < 0.001), (b) MPO (𝑟
𝑠
= 0.748, 𝑝 < 0.001), (c) IL-6 (𝑟
𝑠
= 0.749, 𝑝 < 0.001), (d) HNE (𝑟
𝑠
= 0.749, 𝑝 < 0.001), (e) elafin (𝑟
𝑠
= 0.403, 𝑝 = 0.037),
(f) MMP-2 (𝑟
𝑠
= 0.401, 𝑝 = 0.038), (g) TIMP-1 (𝑟
𝑠
= 0.717, 𝑝 < 0.001), (h) MMP-8/TIMP-1 molar ratio (𝑟
𝑠
= 0.949, 𝑝 < 0.001), and (i) CRP (𝑟
𝑠
= 0.501, 𝑝 = 0.008).
Nine neonates (33%) exhibited prematurity-related adverse
neonatal outcome, all born ≤ 29+0 gestational weeks. Six
(67%) of those had MIAC. Two neonates had early-onset
neonatal sepsis.
Only one of the 16 neonates born after 32 gestational
weeks was born from IAI-case where Ureaplasma was
detected by AF-PCR. AF-LD and AF-Gluc were normal in
this case suggesting colonization. AF-IL-6 concentration was
5.6 ng/mL andAF-MMP-8 concentration was 144 ng/mL, but
these values were not available for the clinician. AF-MMP-9
(𝑝 = 0.006), MPO (𝑝 = 0.011), HNE (𝑝 = 0.034), and MMP-
8/TIMP-1 molar ratio (𝑝 = 0.034) were associated with blood
culture positive neonatal sepsis when the data were adjusted
by gestational age at delivery (data not shown).
4. Discussion
We demonstrated that, among IAI suspected cases, all AF
biomarkers from Cascades 1 and 2 were associated with
MIAC, which was documented in one-fourth of our IAI
suspected cases despite presumed intact membranes. The
association persisted even after adjusting by gestational age
at amniocentesis. Furthermore, in IAI cases AF biomarkers
produced by neutrophils were associatedwith general inflam-
matory biomarker CRP [19] in AF. Additionally, neutrophil
based biomarkers were able to both discriminate cases from
controls after adjusting by gestational age at amniocentesis
and associate with MIAC.
The problem with biomarkers commonly used, that is,
AF-Gluc and AF-LD, is the limited accuracy for MIAC [15,
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Figure 2: Correlation of other AF biomarkers with AF-MMP-8 among controls. Correlation values were (a) MMP-9 (𝑟
𝑠
= −0.223, 𝑝 = 0.21),
(b) MPO (𝑟
𝑠
= 0.609, 𝑝 = 0.002), (c) IL-6 (𝑟
𝑠
= 0.193, 𝑝 = 0.367), (d) HNE (𝑟
𝑠
= 0.671, 𝑝 < 0.001), (e) elafin (𝑟
𝑠
= 0.147, 𝑝 = 0.49), (f) MMP-2
(𝑟
𝑠
= 0.266, 𝑝 = 0.21), (g) TIMP-1 (𝑟
𝑠
= 0.179, 𝑝 = 0.403), (h) MMP-8/TIMP-1 molar ratio (𝑟
𝑠
= 0.845, 𝑝 < 0.001), and (i) CRP (𝑟
𝑠
= −0.294,
𝑝 = 0.16).
20, 21]. AF-MMP-8 and AF-IL-6 have been demonstrated to
provide better accuracy [22] but are not commonly used in
clinical practice. RapidAF biomarkers are needed for optimal
timing of delivery in women with suspected IAI.
We studied several AF biomarkers which form inflamma-
tion related proteolytic cascades. One can identify increased
levels of PMN-derived biomarkers in MIAC cases. IL-6 can
induce PMN extravasation at the site of inflammation, often
triggered by microorganisms or virulence factors associated
[4], and also act as a degranulation inducer.
Proinflammatory neutrophil-derived AF biomarkers
(Cascade 1) associated with general inflammatory biomarker
CRP in IAI cases though suggesting that activated and
degranulating neutrophils are the major source of MMP-8
and MMP-9, MPO (Cascade 1), and HNE (Cascade 2) in the
AF affected by MIAC. AF neutrophils are of maternal origin
[1] reflecting maternal host response to infection. Cascade 3
biomarkers did not detect this since these biomarkers, MMP-
2 and TIMP-1, are not produced and released by neutrophils
[4, 23]. Furthermore, HNE and MPO can proteolytically and
oxidatively inactivate TIMP-1, respectively, thus reducing
the antiproteolytic defensive shield in AF [4, 23]. Infection
leading to imbalance of MMP-8 and TIMP-1 may be related
to initiation of preterm delivery [24].
MMP-9, IL-6, HNE, and elafin have been linked toMIAC
in previous studies [14, 25–28], whereas MMP-2 has been
associated with MIAC in PPROM pregnancies only [25].
TIMP-1 in AF has been linked to MMP-9 [29] and to MIAC
in pregnancies with intact membranes [30], but in this study
MIAC was not determined with PCR, as it was in our study.
Thus, we confirmed and expanded the previous findings in
IAI suspected cases with presumed intact membranes.
8 Disease Markers
Several reports of AF-CRP and preterm delivery exist
[31, 32], but only few include AF-CRP in the diagnosis of
IAI [33]. In the study of Dulay exact AF-CRP values were
not written out, but AF-CRP values differed by MIAC [33].
In that study both pregnancies with and without PPROM
were included. Although AF-CRP is of fetal origin [34], we
found that AF-CRP was not useful in IAI diagnostics or
in predicting adverse neonatal outcome in pregnancies with
presumed intact membranes. MIAC and funisitis have been
associated with umbilical cord CRP-value [35], but our study
had no intention to analyze postnatal cord samples.
We found that infection and inflammation occurred
mainly at low gestational weeks, as also reported by Combs
et al. [16]. So far, no randomized trials exist about the impact
of amniocentesis in the management of preterm labor and
PPROMonneonatal outcome.However, recent observational
studies [36–39] suggest that it could be beneficial. Combs
et al. [16] reported that AF infection or inflammation is
associated with neonatal morbidity. However, we could not
repeat this with any of the biomarkers studied. Smaller
sample size and different clinical setting may explain this
discrepancy.
Although this study had a relatively small sample size,
we were able to show significant differences in biomarker
concentrations between cases and controls.Multicentre study
design is needed for larger sample size. Small sample size
made multivariate analyses or adjustment of neonatal out-
comes by gestational age meaningless. Larger studies are
necessary to determine biomarker cut-off values for clinical
practice and to find out whether a biomarker panel would be
better than any single biomarker. The results have not been
adjusted for gestational diabetes and preeclampsia, which is
a limitation since some controls did have those background
diseases, which may have some immune contribution. How-
ever, in the clinical practice it is important to find a biomarker
working in the whole population, not just in those without
any background diseases. Another limitation is the lack of
molecular biology techniques in the definition of neonatal
sepsis and the lack of microbial culture analysis in controls
in the assessment of MIAC.
To our knowledge, this is the first study reporting the
association of inflammation related proteolytic biomarker
cascades with IAI. In summary, our results highlight the
association of PMN-derived biomarkers with MIAC and IAI
in preterm pregnancies with intact membranes.
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